Rupam Manna, Medical Oncologist,Entrepreneur,interested in Metabolism education and brain science, shared a post on X:
“Evolution of Adjuvant Therapy in Breast Cancer
My latest high-yield practical guide on landmark trials that transformed post-surgical treatment – from uniform chemotherapy to precision, subtype-driven care (2026 update).
- HR+/HER2–: Genomic de-escalation (TAILORx, RxPONDER) + CDK4/6i escalation (monarchE, NATALEE).
- HER2+: Trastuzumab era – dual blockade (APHINITY) + T-DXd for residual disease (KATHERINE/DESTINY-Breast05).
- TNBC: Perioperative pembrolizumab (KEYNOTE-522) + olaparib for BRCA+ (OlympiA).
- Biomarker-driven de-escalation and escalation based on risk and genomics Essential for breast oncology, precision medicine and exam prep.
Save it Share it with your team and trainees Which landmark trial changed your practice the most in early breast cancer? Feedback and discussions welcome!”
Other articles about Breast Cancer on OncoDaily.